Sterling Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sterling Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Sell	5,769 -609	-10%	-$33.4K	0.01%	1005
2026 Q1	$360K	Sell	6,378 -4,893	-43%	-$285K	0.01%	914
2025 Q4	$670K	Sell	11,271 -484	-4%	-$26.4K	0.01%	801
2025 Q3	$637K	Sell	11,755 -900	-7%	-$51.5K	0.01%	824
2025 Q2	$696K	Buy	12,655 +2,157	+21%	+$127K	0.01%	772
2025 Q1	$742K	Sell	10,498 -694	-6%	-$46.7K	0.01%	695
2024 Q4	$736K	Buy	11,192 +3,993	+55%	+$267K	0.01%	730
2024 Q3	$506K	Buy	+7,199	New	+$602K	0.01%	848
2016 Q2	–	Sell	-2,445	Closed	-$202K	–	933
2016 Q1	$202K	Buy	+2,445	New	+$199K	﹤0.01%	864

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sterling Capital Management's BMRN Position: Q2 2026 in Review

Sterling Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 9.5% in Q2 2026, selling an estimated $33.4K and leaving 5,769 shares worth $330K. The position accounts for 0.01% of the portfolio, ranked #1005.

Sterling Capital Management first reported a position in BMRN in Q1 2016 and has held it in 9 quarters since. The position peaked at $742K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Sterling Capital Management held 5,769 shares of BioMarin Pharmaceuticals worth $330K as of Q2 2026.
Sterling Capital Management sold 609 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $33.4K.
BioMarin Pharmaceuticals made up 0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1005 holding.
Sterling Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 9 quarters since.
Sterling Capital Management's BioMarin Pharmaceuticals position peaked at $742K in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.